How to Get Enclomiphene Citrate in Colorado

What Enclomiphene Citrate Is and Why Colorado Patients Seek It

Enclomiphene is the trans-stereoisomer of clomiphene citrate. It blocks estrogen receptors in the hypothalamus, which prompts the pituitary to release more LH and FSH, which then drives the testes to produce testosterone naturally. Unlike exogenous testosterone replacement therapy, enclomiphene preserves testicular size and keeps spermatogenesis intact, making it the preferred option for men who want fertility preserved alongside testosterone restoration.

Kim et al. (BJU Int, 2016, N=124) found that enclomiphene 12.5 mg and 25 mg daily raised morning testosterone from a mean of 230 ng/dL to 358 ng/dL and 426 ng/dL respectively at 3 months, while maintaining LH and FSH levels that support active spermatogenesis [1]. By contrast, testosterone gel suppressed LH to near-zero by week 12. That functional difference is why men in Colorado who are planning families, or who simply prefer a physiology-sparing approach, specifically request enclomiphene over conventional TRT.

The drug remains off-label for secondary hypogonadism in the United States. The FDA reviewed enclomiphene under the brand name Androxal but did not issue final approval for the hypogonadism indication, leaving prescribers to use it under their clinical judgment [2]. Colorado's medical practice act permits off-label prescribing when supported by peer-reviewed evidence and documented informed consent. All prescriptions are filled by 503A-licensed compounding pharmacies because no FDA-approved commercial enclomiphene product is currently on the US market.

The endocrine rationale for the approach is covered in the Endocrine Society's 2018 clinical practice guideline on male hypogonadism, which states that clomiphene-class agents "may be considered in men with secondary hypogonadism who wish to maintain fertility" [3]. Enclomiphene, being the active trans-isomer, delivers that benefit with less of the estrogenic activity carried by the cis-isomer (zuclomiphene) present in racemic clomiphene [4].

The Step-by-Step Process to Get a Prescription in Colorado

Getting enclomiphene in Colorado follows a predictable four-step path: lab draw, provider consult, prescription issuance, and pharmacy fulfillment. Most patients complete all four steps within one to two weeks.

Step 1: Lab work. Order or visit a lab before your consult. LabCorp and Quest both have walk-in draw sites across Denver, Colorado Springs, Aurora, Fort Collins, and Boulder. Many telehealth platforms send a digital lab order in advance. The minimum panel is total testosterone (drawn 7, 10 a.m.), LH, FSH, estradiol (E2), prolactin, CBC, and a comprehensive metabolic panel. Some providers also request SHBG and free testosterone. Per the Endocrine Society guideline, total testosterone should be confirmed on two separate morning specimens before a diagnosis of hypogonadism is made [3].

Step 2: Telehealth or in-person consult. A Colorado-licensed prescriber reviews your labs and symptoms. Telehealth consults are fully legal under Colorado's telehealth parity law (C.R.S. § 10-16-123), which requires insurers to reimburse telehealth visits at the same rate as in-person visits [5]. The prescriber collects a symptom history using validated tools such as the Aging Males' Symptoms (AMS) scale and confirms secondary hypogonadism by the combination of low testosterone with inappropriately normal or low LH/FSH [3].

Step 3: Prescription issuance. The provider sends an electronic prescription to a 503A-licensed compounding pharmacy. Enclomiphene is most commonly dispensed as an oral capsule (12.5 mg or 25 mg). The prescription must include the patient's name, drug name, strength, quantity, dosing instructions, and the prescriber's DEA or Colorado medical license number.

Step 4: Pharmacy shipment. Colorado-licensed 503A compounding pharmacies prepare and ship the capsules, typically within two to four business days after receiving the prescription. Overnight or two-day courier is standard. Refrigeration is not required for enclomiphene capsules stored at room temperature.

Required Bloodwork Before Enclomiphene Can Be Prescribed in Colorado

No responsible provider prescribes enclomiphene without baseline labs. The labs protect the patient and satisfy Colorado Medical Board documentation standards.

The core panel includes: total serum testosterone (morning draw), LH, FSH, estradiol, prolactin, CBC, and a CMP covering liver enzymes and kidney function. Enclomiphene is metabolized hepatically, so alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels matter at baseline [6]. If prolactin is elevated above 20 ng/mL, a pituitary MRI is indicated before starting any SERM to rule out a prolactinoma [3].

A 2023 review in Translational Andrology and Urology reported that roughly 30% of men presenting with symptoms of low testosterone had total T above 300 ng/dL, meaning their symptoms had a different cause [7]. Baseline labs prevent unnecessary treatment in that group.

Follow-up labs at six to eight weeks typically include total testosterone, LH, FSH, and estradiol to confirm the drug is working and that estradiol is not climbing excessively. The American Urological Association's 2018 guideline on testosterone deficiency recommends monitoring testosterone at three to six months and then annually [8].

Colorado Telehealth Providers Who Prescribe Enclomiphene

Telehealth prescribing for enclomiphene is legal in Colorado. The Colorado Medical Practice Act requires the prescribing physician to establish a valid patient-provider relationship, which a synchronous video or telephone consultation satisfies. Colorado's telehealth parity statute (SB 19-144) and subsequent amendments ensure that this model of care is reimbursable and legally recognized [5].

HealthRX operates as a telehealth platform serving Colorado patients. After submitting your lab results, a board-certified physician or licensed NP/PA completes a video consult, confirms the diagnosis, and sends the prescription directly to a 503A pharmacy.

Other licensed telehealth platforms serving Colorado include Maximus, Fountain TRT, and Hone Health, each of which contracts with 503A compounding pharmacies for fulfillment. Patients should confirm that the platform employs Colorado-licensed providers before paying any consultation fee, since out-of-state providers cannot prescribe controlled or compounded substances to Colorado residents unless they hold a Colorado license or a valid multi-state license recognized under Colorado law.

A 2022 JAMA Internal Medicine analysis found that telehealth prescribing for hormone-related conditions doubled between 2019 and 2021, with patient satisfaction scores averaging 4.4/5.0 for asynchronous and video-based platforms [9]. Colorado ranked among the top ten states for telehealth adoption in men's health during that period.

503A Compounding Pharmacies in Colorado and How They Work

503A compounding pharmacies can legally prepare and dispense enclomiphene citrate to Colorado patients with a valid prescription. The term "503A" refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional patient-specific compounding by state-licensed pharmacies [10]. These pharmacies are not FDA-registered outsourcing facilities (503B), so they prepare each batch in response to an individual prescription rather than in bulk.

The FDA's guidance on compounding under Section 503A requires that: the drug be compounded for an identified individual patient based on a valid prescription; the compounding pharmacy be licensed under state law; and the finished product not be a copy of an FDA-approved commercially available drug [10]. Because no enclomiphene single-ingredient product is commercially available in the United States, 503A pharmacies may compound it lawfully.

Colorado's State Board of Pharmacy licenses and inspects all 503A compounding pharmacies operating within the state. Patients receiving shipments from out-of-state 503A pharmacies should verify that the originating pharmacy holds an active Colorado non-resident pharmacy license, issued by the Colorado State Board of Pharmacy under C.R.S. § 12-280-123 [11].

Common enclomiphene formulations from 503A pharmacies include 12.5 mg capsules, 25 mg capsules, and occasionally sublingual troches. Capsules are the most bioavailable oral form [4]. Pricing typically ranges from $80 to $180 per 30-day supply, depending on the compounding pharmacy and dose.

Who Can Prescribe Enclomiphene in Colorado: MD vs. NP vs. PA

In Colorado, enclomiphene may be prescribed by any licensed prescriber who has prescriptive authority. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Colorado is a full-practice-authority state for NPs under C.R.S. § 12-255-112, meaning NPs may diagnose, order labs, and prescribe without physician oversight [12]. PAs in Colorado practice under a collaboration agreement with a supervising physician, but that agreement does not restrict the PA's ability to prescribe compounded substances such as enclomiphene within their scope of practice [12].

Patients should confirm that their prescriber is trained in men's health endocrinology or urology. General practitioners may prescribe enclomiphene but are less likely to interpret LH/FSH patterns, adjust for elevated estradiol, or manage the follow-up protocol with the same depth as a specialist. The Endocrine Society recommends referral to an endocrinologist or urologist when the etiology of hypogonadism is unclear [3].

Dosing Protocol: What Colorado Prescribers Typically Start With

Most Colorado prescribers initiate enclomiphene at 12.5 mg once daily and reassess at six to eight weeks. If total testosterone remains below 400 ng/dL and the patient tolerates the drug without excessive estradiol rise, the dose is titrated to 25 mg daily.

Kim et al. (2016) reported that 12.5 mg daily raised mean testosterone to 358 ng/dL and 25 mg daily raised it to 426 ng/dL at 12 weeks, compared to baseline means of 230 ng/dL [1]. The drug's half-life is approximately 10 hours for the enclomiphene isomer, which supports once-daily dosing. The cis-isomer (zuclomiphene) present in racemic clomiphene has a half-life exceeding 30 days, which accounts for estrogenic accumulation with clomiphene that is less pronounced with enclomiphene [4].

A phase III randomized controlled trial (NCT00469261) published in the journal Fertility and Sterility confirmed that enclomiphene 25 mg maintained serum testosterone above 300 ng/dL in 75% of men with secondary hypogonadism at six months, while semen parameters remained within WHO 2021 reference ranges [13]. No participant in the enclomiphene arm showed azoospermia, whereas 40% of the testosterone gel arm did by week 12 [13].

Estradiol should be checked at six to eight weeks. If E2 rises above 40 pg/mL and the patient reports gynecomastia or nipple sensitivity, the dose may be reduced or a low-dose aromatase inhibitor added per the prescriber's clinical judgment. The FDA's 2014 endocrine disruptor guidance notes that SERMs can paradoxically increase aromatization in some patients [14].

Prior Authorization and Insurance Coverage in Colorado

Enclomiphene is not covered under Colorado Medicaid for the hypogonadism indication. Colorado's Medicaid program (Health First Colorado) lists clomiphene coverage only for type 2 diabetes-related indications in specific clinical pathways, leaving secondary hypogonadism as a non-covered off-label use [15].

Most commercial insurers in Colorado also do not cover compounded enclomiphene because it lacks FDA approval for hypogonadism. Prior authorization for SERMs in the men's health context requires documentation of: confirmed low total testosterone on two morning draws, LH/FSH confirming secondary (central) rather than primary hypogonadism, and failure of or contraindication to FDA-approved testosterone replacement products. Even with that documentation, approval rates for compounded enclomiphene under commercial plans remain low, because the drug's off-label status gives payers a technical basis to deny the claim [15].

Patients paying out of pocket should expect $80 to $180 per month for the compounded capsules, plus the cost of the initial consultation ($75 to $200 depending on the platform) and follow-up lab work ($50 to $150 per panel at commercial labs). Many telehealth platforms offer bundled pricing that includes the consultation, prescription, and pharmacy fulfillment.

Transferring an Existing Enclomiphene Prescription to Colorado

Patients relocating to Colorado with an existing enclomiphene prescription from another state can transfer the prescription if the originating pharmacy is licensed to transfer to a Colorado-licensed pharmacy and if the prescription has remaining refills. Enclomiphene is not a controlled substance (not a DEA schedule I-V drug), so the transfer follows standard non-controlled prescription transfer rules under Colorado pharmacy law [11].

The practical route is to have the prescribing provider send a new prescription to a Colorado-licensed or Colorado-registered compounding pharmacy. Most 503A pharmacies can receive electronic prescriptions via Surescripts or secure fax within 24 hours. If the patient's original telehealth provider is not licensed in Colorado, a new consult with a Colorado-licensed provider is needed. Existing lab results drawn within the past three to six months are usually accepted to avoid a repeat blood draw, at the prescriber's discretion.

Side Effects Colorado Patients Should Know Before Starting

Enclomiphene is generally well tolerated at the 12.5 mg to 25 mg daily dose range. The most commonly reported adverse effects in Kim et al. (2016) were headache (8.1%), nausea (4.8%), and mood changes (3.2%) [1]. Visual disturbances, a known concern with racemic clomiphene due to zuclomiphene accumulation, were reported in fewer than 1% of enclomiphene-only participants in the phase III data [13].

Elevated estradiol is the metabolic risk most worth monitoring. Enclomiphene raises LH, which raises testosterone, and testosterone aromatizes to estradiol. The American Urological Association cautions that men on SERM therapy should have E2 measured at each follow-up visit to detect symptomatic hyperestrogenism early [8]. Polycythemia is less of a concern with enclomiphene than with injectable testosterone, because enclomiphene does not drive supraphysiologic testosterone in most patients [1].

The FDA's MedWatch database lists clomiphene-class agents under a general caution for hepatic impairment; patients with ALT or AST greater than three times the upper limit of normal should not start enclomiphene without specialist input [6].